Efficacy of tumor necrosis factor and interleukin-10 analysis in the follow-up of nonalcoholic fatty liver disease progression

Indian Journal of Clinical Biochemistry

Volumn 28, Issue 2, 2013, Pages 141-146

  Zahran, Walid E ^a   Salah El Dien, Kholoud A ^a   Kamel, Philip G ^a   El Sawaby, Ahmed Shawky ^b  

^a Ain Shams University   (Egypt)

^b AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Diagnosis; Interleukin 10; Non alcoholic fatty liver disease; Progression; Steatohepatitis; Tumor necrosis factor alpha

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 10; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATIONAL STUDY; DIABETIC PATIENT; DISEASE COURSE; FEMALE; FIBROSIS; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; LIVER FUNCTION TEST KIT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL;

EID: 84891832887     PISSN: 09701915     EISSN: 09740422     Source Type: Journal    
DOI: 10.1007/s12291-012-0236-5     Document Type: Article

References (40)

1. Zelber-Sagi S, Lotan R, Shlomai A, Webb M, Harrari G, Buch A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol. 2012;56:1145-51.
2. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917-23.
3. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142(4):711-25.
4. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004;2:1048-58.
5. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998;114:842-5.
6. Albano E. Oxidative mechanisms in the pathogenesis of alcoholic liver disease. Mol Aspects Med. 2008;29:9-16.
7. Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta. 2011;412:1297-305.
8. Wong VW, Chan HL, Hui AY, Chan KF, Liew CT, Chan FK, Sung JJ. Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. Aliment Pharmacol Ther. 2004;20(1):45-9.
9. Angulo P. Non alcoholic fatty liver disease. N Engl J Med. 2002;346:1221-31.
10. Vanni E, Bugianesia E, Kotronen A, De Minicis S, Yki-Järvinen H, Svegliati-Baroni G. From the metabolic syndrome to NAFLD or vice versa? Dig Liver Dis. 2010;42:320-30.
11. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med. 2012;52:59-69.
12. Crews FT, Bechara R, Brown LA, Guidot DM, Mandrekar P, Oak S, Qin L, Szabo G, Wheeler M, Zou J. Cytokines and alcohol. Alcohol Clin Exp Res. 2006;30:720-30.
13. Cameron RG, Neuman MG. Novel morphologic findings in alcoholic liver disease. Clin Biochem. 1999;32(7):579-84.
14. Das SK, Balakrishnan V. Role of cytokines in the pathogenesis of non-alcoholic fatty liver disease. Ind J Clin Biochem. 2011;26(2):202-9.
15. Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):179-85.
16. Mottin CC, Moretto M, Padoin AV. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg. 2004;14:635-7.
17. Freidewald WT, Levy RJ, Fredrickson DS. Estimation of concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
18. Stepaniak J, Shuster J, Sundick R. Production and determination of recombinant human cytokines. J Cytokine Res. 1995;19:515-26.
19. Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment cytokines in NAFLD. Am J Gastroenterol. 2008;103:1036-42.
20. Lu H, Zeng L, Liang B, Shu X, Xie D. High prevalence of coronary heart disease in type 2 diabetic patients with non-alcoholic fatty liver disease. Arch Med Res. 2009;40:571-5.
21. Edens M, Kuipers F, Stolk R. Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers. Obes Rev. 2009;10:412-9.
22. Collier J. Non-alcoholic fatty liver disease. Medicine. 2007;35(2):86-8.
23. Giorgio R, Wolfgang K, Joseph S, Klaus P. Non-alcoholic fatty liver disease in obese children evaluated by magnetic resonance imaging. Acta Pediatr. 2006;95(7):833-7.
24. Steve C, Anna M. Role of inflammation in nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2005;21(6):702-7.
25. Riley TR, Taheri M, Schreibman IR. Does weight history affect fibrosis in the setting of chronic liver disease? J Gastrointest Liver Dis. 2009;18(3):299-302.
26. Bugianesi E, Zannoni C, Vanni E, Marzocchi R, Marchesini G. Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship? Dig Liver Dis. 2004;36(3):165-73.
27. Uchil D, Pipalia D, Chawla M, Patel R, Maniar S, Narayani, Juneja A. Non-alcoholic fatty liver disease (NAFLD) - The hepatic component of metabolic syndrome. J Assoc Physicians India. 2009;57:201-4.
28. Simonen P, Kotronen A, Hallikainen M, Sevastianova K, Makkonen J, Hakkarainen A, et al. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol. 2011;54:153-9.
29. Nobili V, Alisi A, Vania A, Tiribelli C, Pietrobattista A, Bedogni G. The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Med. 2009;7(21).
30. Mouralidarane A, Oben JA, Soeda J. Pathophysiology and clinical management of nonalcoholic fatty liver disease. Medicine. 2011;39(10):592-6.
31. Peraldi P, Hotamisligil GS, Buurman WA, White MF, Spiegelman BM. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem. 1996;271(22):13018-22.
32. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 2000;343:1467-76.
33. Wei Y, Rector RS, Thyfault JP, Ibdah JA. Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol. 2008;14(2):193-9.
34. Zhang L, Wang XZ. Interleukin-10 and chronic liver disease. World J Gastroenterol. 2006;12(11):1681-5.
35. Straczkowski M, Kowalska I, Nikolajuk A, Krukowska A, Gorska M. Plasma interleukin-10 concentration is positively related to insulin sensitivity in young healthy individuals. Diabetes Care. 2005;28(8):2036-7.
36. Uysal S, Armutcu F, Aydogan T, Akin K, Ikizek M, Yigitoglu MR. Some inflammatory cytokine levels, iron metabolism and oxidan stress markers in subjects with nonalcoholic steatohepatitis. Clin Biochem. 2011;44(17-18):1375-9.
37. Angulo P. Treatment of non alcoholic fatty liver disease. Ann Hepatol. 2002;1(1):12-9.
38. Cintra DE, Pauli JR, Araújo EP, Moraes JC, De Souza CT, Milanski M, et al. Interleukin-10 is a protective factor against diet-induced insulin resistance in liver. J Hepatol. 2008;48(4):628-37.
39. Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol. 2012;18(8):727-35.
40. Hashem RM, Mahmoud MF, El-Moselhy MA, Soliman HM. Interleukin-10 to tumor necrosis factor-alpha ratio is a predictive biomarker in nonalcoholic fatty liver disease: interleukin-10 to tumor necrosis factor-alpha ratio in steatohepatitis. Eur J Gastroenterol Hepatol. 2008;20(10):995-1001.